{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m cidofovir
to a specific field?
Status:
US Approved Rx
(2008)
Source:
BLA125249
(2008)
Source URL:
First approved in 2008
Source:
BLA125249
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
BLA125118
(2005)
Source URL:
First approved in 2005
Source:
BLA125118
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
NDA021060
(2004)
Source URL:
First approved in 2004
Source:
NDA021060
Source URL:
Class:
PROTEIN
Conditions:
Ziconotide (PRIALT; SNX-111) is a neuroactive peptide, which was approved by FDA in 2004 for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals.
Status:
US Approved Rx
(2022)
Source:
BLA761173
(2022)
Source URL:
First approved in 2002
Source:
BLA125031
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
BLA761216
(2021)
Source URL:
First approved in 2002
Source:
BLA125057
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
First approved in 1998
Source:
BLA103980
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2018)
Source:
BLA761080
(2018)
Source URL:
First approved in 1991
Source:
BLA103353
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1966)
First approved in 1966
Class:
PROTEIN
Status:
Investigational
Source:
INN:vecantoxatug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efzilonkofusp alfa [INN]
Source URL:
Class:
PROTEIN
